Committed to drug delivery excellence. Our vision is to enable customer success with high quality and innovative drug delivery solutions that improve patient well-being.
With over 50 years of experience, we are empowering customer success through innovative drug-delivery solutions that improve patient quality of life. Safety Needles Retractable
Prefillable Syringes* (PFS) manufactured per year1
Products used by more than 500 Pharmaceutical and Biotechnology companies.2
BD customers include 27 of the top 30 pharmaceutical companies in the world.3
~70% of the top 100 pharmaceutical companies around the world rely BD Medical-Pharmaceutical Systems prefillable drug-delivery systems for a wide variety of therapeutic applications.4
BD has generated over 4000 patents that are enforced in more than 25 countries.5
There is a patient at the end of each of the billions of drug delivery devices that we make at BD. That is why we have invested in deep knowledge around patient experience, injection science and combination product development to anticipate customer challenges, manage complexities, and reduce risks. We also invest heavily to support our commitment to quality. Through our extensive global manufacturing network, we aim to offer security of supply and business continuity to our customers.
These, plus our ability to leverage the industry and health authority partnerships of a global healthcare company, are game changing advantages that BD brings to our customers’ drug delivery challenges.
We leverage these assets as we develop innovative solutions that provide peace of mind to customers and contribute to greater patient well-being.
Solutions to meet your needs across therapeutic areas
BD Medical - Pharmaceutical Systems manufactures and sells prefillable drug delivery systems to pharmaceutical and biotech companies.
BD uses proprietary needle technologies to develop needles that optimize your drug delivery.
Featuring a comprehensive portfolio of innovative prefillable syringe systems, BD offers drug delivery solutions designed to help decrease development risk, improve speed to market, and increase flexibility to meet patients’ needs across a wide range of drug types and therapeutic areas.
BD Safety & Shielding Systems provide pharmaceutical companies with a wide range of both active and passive manual injection solutions available in 0.5ml, 1ml, and 2.25ml formats, suitable for a variety therapeutic indications.
BD offers an extensive portfolio of patient centric, self-administered drug delivery solutions including disposable autoinjectors, disposable variable dose pen injectors, and wearable injectors designed to deliver a wide range of volumes and viscosities and help de-risk combination product development.
To fulfill our system approach, we provide a complete set of components for your prefillable syringe systems.
BD Effivax™ Glass Prefillable Syringe
BD SCF™ PremiumCoat® Plunger Stopper
BD Neopak™ XtraFlow™ Glass Prefillable Syringe
BD Hylok™ Glass Prefillable Syringe
BD Neopak™ XSi™ Glass Prefillable Syringe
BD Hypak™ for Vaccines Glass Prefillable Syringe
BD UltraSafe Plus™ 1mlL Passive Needle Guard
BD Sterifill Advance™ 50ml Polymer Prefillable Syringe
BD Neopak™ Glass Prefillable Syringe
BD acquires Safety Syringes Inc.
BD AutoShield Duo™ Safety Pen Needle
BD Hypak™ for Biotech Glass Prefillable Syringe
BD Hypak Physiolis™ Glass Prefillable Syringe
BD Sterifill™ Polymer Prefillable Syringe
BD Eclipse™ Needle Shielding System
BD Accuspray™ Nasal Spray System
BD SCF™ FluroTec® Plunger Stoppers
BD Uniject™ Auto-Disable Prefillable Injection System
BD Sterifill™ Polymer Prefillable Syringe
BD SafetyGlide™ Needle Shielding System
BD Hypak™ Glass Disposable Syringe
BD Physioject™ - recognized by the Arthritis Foundation®
BD Intevia™ - Best Practices Award
BD Libertas™ wins prestigious Good Design® Award
BD Libertas™ - Design Award
World’s Most Admired Companies
Fill out our form to have one of our experts contact you.
BDM-PS Financial file November 2022, “Actual FY22” Permiter.
BDM-PS Financial file November 2020, "Actual FY20" Permiter.
BD Customers compared to Evaluate Pharma ranking FY2019
IQVIA: IQVIA dataset extracted on March 11th, 2021, from the IQVIA Smart MIDAS' on-line platform, includes WW sales of injectable drugs. Top 100 Corporation (based on IQVIA standard units 2020) selling PFS, Autoinjectors or Pens. TA included: Acute biologics, Anticoagulants, Chronic, Small molecules, Vaccines
BDM-PS Patents – In force – Worldwide – October 2021.
Solutions to meet your needs across therapeutic areas
BD Medical - Pharmaceutical Systems manufactures and sells prefillable drug delivery systems to pharmaceutical and biotech companies.
BD uses proprietary needle technologies to develop needles that optimize your drug delivery.
Featuring a comprehensive portfolio of innovative prefillable syringe systems, BD offers drug delivery solutions designed to help decrease development risk, improve speed to market, and increase flexibility to meet patients’ needs across a wide range of drug types and therapeutic areas.
BD Safety & Shielding Systems provide pharmaceutical companies with a wide range of both active and passive manual injection solutions available in 0.5ml, 1ml, and 2.25ml formats, suitable for a variety therapeutic indications.
BD offers an extensive portfolio of patient centric, self-administered drug delivery solutions including disposable autoinjectors, disposable variable dose pen injectors, and wearable injectors designed to deliver a wide range of volumes and viscosities and help de-risk combination product development.
To fulfill our system approach, we provide a complete set of components for your prefillable syringe systems.
Fill out our form to have one of our experts contact you.
BD understands the drug development process and objectives at each stage and offers a wide range of services to help develop container/device strategy and life cycle management plan for drugs.
BD Pharmaceutical Services and Solutions are designed to help you achieve your combination product goals, from development to launch.
BD PartnerPath™ Program aims to support pharmaceutical organizations that value speed to market in combination product development.1
We’ve built our services and capabilities around a deep understanding of the combination product development process and the key objectives at each stage, from discovery to delivery.
We are committed to partnering for your sustained commercial success.
Effective system integration can be critical to the success of combination products for pharmaceutical companies.1
We manufacture our solutions with a strict focus on continuously advancing quality, consistency and capacity.
Fill out our form to have one of our experts contact you.
View research articles published in a journal and written by experts sharing study results that offer you insight into a particular topic.
View a scientific poster, such as those used for display at BD tradeshows or seminars to provide detailed information on a research topic
Understand BD Products and services.
Learn more about order details, product specs, and technical information by viewing a brochure
Visit the BD Medical - Pharmaceutical Systems webinar portal
Watch a video to be educated about BD products or services
View promotions or announcements for BD products and services
Fill out our form to have one of our experts contact you.
BD Launches Next Generation Prefillable Vaccine Syringe Designed for Reliability, Efficiency
BD Effivax™ Glass Prefillable Syringe Features Enhanced Technology that Builds on Company’s Decades of Expertise in the Prefillable Syringe Market and Supports Customers’ Manufacturing Needs FRANKLIN LAKES, N.J. (September 13, 2022) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today introduced a next-generation glass prefillable syringe (PFS) that sets a new standard in performance for vaccine PFS with new and tightened specifications for processability, cosmetics, contamination and integrity.1
BD and Mitsubishi Gas Chemical have signed a letter of intent (LOI) to discuss a partnership agreement to explore
Companies to work together with the aim of optimizing advanced technologies for use in prefillable syringes FRANKLIN LAKES, N.J. (May 18, 2022) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Mitsubishi Gas Chemical Company, Inc. (MGC), a R&D-oriented chemical manufacturer based in Tokyo, Japan, today announced that they have entered into an agreement to investigate further development of OXYCAPT™ - an innovation from MGC that integrates the best of plastic and glass for plastic syringes.
Fill out our form to have one of our experts contact you.
Syringe 0.5 © 2024 BD. All rights reserved. BD and the BD Logo are trademarks of Becton, Dickinson and Company. All other trademarks are the property of their respective owners.